NSE: GRANULES | BSE: 532482

Mid-range Performer

Download real time

509.40 -14.50 (-2.77%)

29.35% Fall from 52W High

1.1M NSE+BSE Volume

NSE 13 Jun, 2025 3:31 PM (IST)

12,355.2

Market Cap

High in industry

1.0

Beta 1Year

Average volatility

Granules India Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GRANULES, BSE:532482 Granules India Ltd.

Search Inside the pdf :

Granules India Ltd.

06 Jun 2025

509.40

-2.77%

GRANULES INDIA

Accumulate: Granules India Ltd.

Target

Geojit BNP Paribas

Validation activities have begun in Phase 2, Genome Valley, in this quarter. Also, the company continues to invest in research and development efforts aimed at building a pipeline of high-value molecules, with a focus on backward integration, especially in the oncology and CNS segment. The company has filed its first oncology molecule in this quarter....

Granules India Ltd. is trading above its 100 day SMA of 507.7

Granules India Ltd.

28 May 2025

509.40

-2.77%

Broadly in-line quarter; margin resilience led by FDF

Buy: Granules India Ltd.

Target

Motilal Oswal

Granules India (GRAN) delivered a slightly better-than-expected revenue in 4QFY25. However, it reported largely in-line EBITDA/PAT for the quarter.

Granules India Ltd. has an average target of 672.80 from 5 brokers.

Granules India Ltd.

17 Feb 2025

509.40

-2.77%

GRANULES INDIA

Accumulate: Granules India Ltd.

Target

Geojit BNP Paribas

Granules India Ltd. is trading below its 150 day SMA of 531.6

Granules India Ltd.

25 Jan 2025

509.40

-2.77%

Finished dosages remain the key earnings driver

Buy: Granules India Ltd.

Target

Motilal Oswal

Granules India (GRAN) delivered better-than-expected revenue, while EBITDA/PAT stood in line for the quarter. The traction in finished dosage (FDF) remained robust for six quarters now.

Granules India Ltd. has an average target of 672.80 from 5 brokers.

Granules India Ltd.

08 Nov 2024

509.40

-2.77%

New product launches and capacity expansion to drive growth

Buy: Granules India Ltd.

Target

KRChoksey

Granules revenue missed our estimate due to a significant decline in API and PFI sales. EBITDA missed our estimate due to higher-than-expected employee expenses.

Granules India Ltd. has an average target of 672.80 from 5 brokers.

Granules India Ltd.

06 Nov 2024

509.40

-2.77%

Plants Resuming Operations and Upcoming Product Launches

Buy: Granules India Ltd.

Target

Sharekhan

Revenues stood at Rs. 957 crore, falling 19% y-o-y and 18% q-o-q, falling 5% short of our estimates.

Granules India Ltd. is trading above its 100 day SMA of 507.7

Granules India Ltd.

12 Sep 2024, 12:00AM

509.40

-2.77%

Gagillapur site under a cloud

Buy: Granules India Ltd.

Motilal Oswal

Granules India (GRAN) was issued a Form 483 with six observations for its Gagillapur site after a recent USFDA inspection.

Geojit BNP Paribas increased Accumulate price target of Granules India Ltd. to 599.0 on 06 Jun, 2025.

Granules India Ltd.

19 Aug 2024

509.40

-2.77%

API decline to continue in FY25E

Buy: Granules India Ltd.

Recommendation Target

KRChoksey

GRANULES is expected to continue to see strong growth in FDFs with growth in new products; partially offset by continued weakness in APIs with higher channel inventory for Paracetamol APIs in regulated markets.
We expect the company to clock in 14.0% and 33.3% CAGR rise in revenue and net income, respectively, over FY24-FY26E (vs. 13.4% and 30.2% CAGR rise seen over FY24-FY26E earlier).

Granules India Ltd. is trading below its 150 day SMA of 531.6

Granules India Ltd.

16 Aug 2024

509.40

-2.77%

GRANULES INDIA

Accumulate: Granules India Ltd.

Target

Geojit BNP Paribas

Granules India Ltd. has an average target of 672.80 from 5 brokers.

Granules India Ltd.

31 Jul 2024

509.40

-2.77%

FD and low base doubled earnings YoY

Buy: Granules India Ltd.

Target

Motilal Oswal

Granules India (GRAN) posted in-line revenue in 1QFY25. However, it delivered better-than-estimated 1QFY25 EBITDA/PAT led by the increased share of formulation sales.

Granules India Ltd. has an average target of 672.80 from 5 brokers.

Is Granules India Ltd. worth buying?

860 Votes:

Buy 84.07%

Sell 10.23%

Hold 5.7%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf